Glow LifeTech (TSE:GLOW)
:GLOW
Want to see TSE:GLOW full AI Analyst Report?
Top Page
Glow LifeTech
(GLOW)
Select Model
Select Model
Rating:45Neutral
Price Target:
C$0.04
▼(-26.67% Downside)
Action:ReiteratedDate:05/05/26
The score is primarily held back by ongoing losses and negative free cash flow despite improving cash burn and rising revenue. Technical signals are weak-to-neutral with price below longer-term averages and a negative MACD, and valuation support is limited because earnings are negative and no dividend yield is available.
Positive Factors
Rapid Revenue Growth
Sustained double‑digit revenue growth indicates improving commercial traction and product adoption. Over 2–6 months this suggests the company can scale sales processes, improve utilization of fixed costs, and create a foundation for margin expansion as revenues continue to normalize upward.
Negative Factors
Ongoing Losses and Negative Free Cash Flow
Persistent negative free cash flow means the business is not yet self‑funding and will likely need external capital to sustain growth. Over a multi‑month horizon this increases dilution and constrains strategic options, making long‑term planning dependent on successful financing or cash‑flow improvement.
Read all positive and negative factors
Positive Factors
Negative Factors
Rapid Revenue Growth
Sustained double‑digit revenue growth indicates improving commercial traction and product adoption. Over 2–6 months this suggests the company can scale sales processes, improve utilization of fixed costs, and create a foundation for margin expansion as revenues continue to normalize upward.
Read all positive factors
Glow LifeTech (GLOW) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$8.65M
Dividend YieldN/A
Average Volume (3M)266.05K
Price to Earnings (P/E)374.0
Beta (1Y)0.46
Revenue Growth138.76%
EPS Growth84.75%
CountryCA
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)<0.01
Shares Outstanding192,235,550
10 Day Avg. Volume165,602
30 Day Avg. Volume266,047
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)3.82
Price to Sales (P/S)5.04
P/FCF Ratio-87.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Glow LifeTech Business Overview & Revenue Model
Company Description
Glow Lifetech Corp., a biotechnology company, focuses on producing nutraceutical and cannabinoid-based products in North America. The company engages in the commercialization of two technologies, such as MyCell Enhanced technology, a nutraceutical...
Glow LifeTech Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
58
Neutral
Cash Flow
41
Neutral
| Breakdown | Dec 2025 | Mar 2025 | Jun 2024 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.05M | 836.19K | 43.93K | 0.00 | 0.00 |
| Gross Profit | 346.11K | 591.00K | -759.18K | -263.26K | -43.39K |
| EBITDA | -471.01K | -1.24M | -1.31M | -1.92M | -4.59M |
| Net Income | -617.86K | -2.66M | -1.59M | -2.24M | -11.31M |
Balance Sheet | |||||
| Total Assets | 3.92M | 3.72M | 1.91M | 2.31M | 3.76M |
| Cash, Cash Equivalents and Short-Term Investments | 1.37M | 1.29M | 34.00 | 75.19K | 746.02K |
| Total Debt | 56.19K | 404.08K | 171.75K | 147.36K | 39.93K |
| Total Liabilities | 1.21M | 1.15M | 2.35M | 1.14M | 328.03K |
| Stockholders Equity | 2.71M | 2.57M | -433.12K | 1.16M | 3.44M |
Cash Flow | |||||
| Free Cash Flow | -118.20K | -1.36M | -490.86K | -1.36M | -3.62M |
| Operating Cash Flow | -15.03K | -1.35M | -417.26K | -1.30M | -3.18M |
| Investing Cash Flow | -102.18K | 16.70K | -60.91K | 18.31K | -541.41K |
| Financing Cash Flow | 191.39K | 2.62M | 445.01K | 491.44K | 4.59M |
Glow LifeTech Technical Analysis
Neutral
0.06
Price Trends
0.05
Negative
0.06
Negative
0.05
Negative
Market Momentum
>-0.01
Positive
50.57
Neutral
-16.67
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:GLOW, the sentiment is Neutral. The current price of 0.06 is above the 20-day moving average (MA) of 0.05, above the 50-day MA of 0.05, and above the 200-day MA of 0.05, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 50.57 is Neutral, neither overbought nor oversold. The STOCH value of -16.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:GLOW.
Glow LifeTech Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | C$16.88M | -7.66 | -78.88% | ― | 125.00% | 25.37% | |
45 Neutral | C$8.65M | 374.02 | -95.68% | ― | 138.76% | 84.75% | |
44 Neutral | C$6.36M | -2.97 | ― | ― | ― | ― | |
42 Neutral | C$11.74M | -5.25 | 21.59% | ― | ― | -36.36% |
* Healthcare Sector Average
TSE:GLOW
Glow LifeTech
0.05
-0.02
-25.00%
TSE:CSCI
COSCIENS Biopharma
2.63
-2.32
-46.87%
TSE:KNE
Kane Biotech
0.04
-0.05
-56.25%
TSE:QPT
Quest Pharmatech
0.04
>-0.01
-11.11%
TSE:PREV
PreveCeutical Medical
0.02
>-0.01
-33.33%
TSE:MDMA
PharmAla Biotech Holdings, Inc.
0.16
<0.01
3.33%
Glow LifeTech Corporate Events
Business Operations and StrategyFinancial Disclosures
Glow Lifetech Delivers Triple-Digit Revenue Growth and Turns Cash-Flow Positive in 2025
Positive
Apr 8, 2026
Glow Lifetech posted a transformational 2025, with net revenue rising 146% to $2.05 million and gross profit up 130% while maintaining a robust 66% gross margin. The company cut total expenses slightly, sharply reduced cash used in operations, and...
Business Operations and StrategyFinancial Disclosures
Glow Lifetech Slashes Warrant and Option Overhang to Bolster Balance Sheet
Positive
Mar 27, 2026
Glow Lifetech has sharply streamlined its capital structure in the first quarter of 2026 by eliminating more than 41 million outstanding share purchase warrants and just over 5 million stock options, most of which expired unexercised, while a port...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.